MarketCap
Facebook
X
Telegram
Axon Enterprise EV/EBITDA Ratio | AXON
Annual EV/EBITDA Ratio Axon Enterprise
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.57 K | 388 | 121 | 133 | -63.9 | -1.24 K | -6.82 K | 79.5 | 64.9 | 35.8 | 20.6 | 40.9 | 26.3 | 15.3 | 192 | 109 | 66.6 | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.57 K | -6.82 K | -309 |
EV/EBITDA Ratio of other stocks in the Biotechnology industry
| Issuer | EV/EBITDA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Eiger BioPharmaceuticals
EIGR
|
-0.433 | - | -9.21 % | $ 2.55 M |  USA |
 |
Albireo Pharma
ALBO
|
-3.46 | - | -0.23 % | $ 916 M | USA |
 |
BELLUS Health
BLU
|
-20.9 | - | - | $ 2.47 B |  Canada |
 |
bluebird bio
BLUE
|
-2.04 | - | - | $ 546 M | USA |
 |
Intra-Cellular Therapies
ITCI
|
-113 | - | - | $ 13.6 B | USA |
 |
IGM Biosciences
IGMS
|
-1.38 | - | - | $ 76.9 M | USA |
 |
Marinus Pharmaceuticals
MRNS
|
-4.05 | - | - | $ 29.6 M | USA |
 |
Merrimack Pharmaceuticals
MACK
|
-101 | - | - | $ 216 M | USA |
 |
CASI Pharmaceuticals
CASI
|
0.542 | - | - | $ 35.4 M | USA |
 |
ContraFect Corporation
CFRX
|
-0.383 | - | -5.16 % | $ 5.39 M | USA |
 |
Sigilon Therapeutics
SGTX
|
-1.08 | - | - | $ 728 M | USA |
 |
Rubius Therapeutics
RUBY
|
-0.028 | - | -33.55 % | $ 7.81 M | USA |
 |
Aptinyx
APTX
|
0.293 | - | -39.0 % | $ 4.57 M | USA |
 |
TRACON Pharmaceuticals
TCON
|
0.288 | - | -1.38 % | $ 46.8 M | USA |
 |
Mirati Therapeutics
MRTX
|
-3.35 | - | - | $ 3.3 B | USA |
 |
Revance Therapeutics
RVNC
|
-3.18 | - | - | $ 309 M | USA |
 |
Allogene Therapeutics
ALLO
|
-3.13 | $ 0.93 | -11.99 % | $ 205 M | USA |
 |
InVivo Therapeutics Holdings Corp.
NVIV
|
0.956 | - | -37.48 % | $ 476 K | USA |
 |
Epizyme
EPZM
|
-0.12 | - | - | $ 249 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
0.361 | - | -9.72 % | $ 5.89 M | USA |
 |
ORIC Pharmaceuticals
ORIC
|
-7.05 | $ 8.9 | -3.63 % | $ 781 M | USA |
 |
Forward Pharma A/S
FWP
|
-132 | - | -0.75 % | $ 18.7 M |  Danmark |
 |
Orchard Therapeutics plc
ORTX
|
-5.82 | - | 1.02 % | $ 90.8 M |  Britain |
 |
La Jolla Pharmaceutical Company
LJPC
|
11.3 | - | - | $ 154 M | USA |
 |
Oyster Point Pharma
OYST
|
-2.51 | - | - | $ 300 M | USA |
 |
Nabriva Therapeutics plc
NBRV
|
-0.365 | - | - | $ 4.55 M |  Irlanda |
 |
Intercept Pharmaceuticals
ICPT
|
-60.9 | - | - | $ 643 M | USA |
 |
NGM Biopharmaceuticals
NGM
|
-0.613 | - | - | $ 127 M | USA |
 |
Regulus Therapeutics
RGLS
|
0.619 | - | - | $ 155 M | USA |
 |
9 Meters Biopharma
NMTR
|
-0.847 | - | -42.97 % | $ 1.05 M | USA |
 |
Chinook Therapeutics
KDNY
|
-7.76 | - | - | $ 2.6 B | USA |
 |
Lumos Pharma
LUMO
|
-0.078 | - | - | $ 35.3 M | USA |
 |
Syros Pharmaceuticals
SYRS
|
-0.204 | - | -8.44 % | $ 3.4 M | USA |
 |
NanoViricides
NNVC
|
-3.68 | $ 1.44 | 8.27 % | $ 29.1 M | USA |
 |
Gamida Cell Ltd.
GMDA
|
-3.61 | - | -18.25 % | $ 5.04 M |  Israel |
 |
GT Biopharma
GTBP
|
0.233 | $ 3.99 | -7.64 % | $ 22 M | USA |
 |
Aravive
ARAV
|
-0.832 | - | -13.39 % | $ 1.45 M | USA |
 |
Bellerophon Therapeutics
BLPH
|
-3.44 | - | -74.18 % | $ 955 K | USA |
 |
BioLineRx Ltd.
BLRX
|
-550 | $ 1.52 | -3.8 % | $ 3.75 B | Israel |
 |
VistaGen Therapeutics
VTGN
|
-0.055 | $ 0.18 | -0.46 % | $ 6.85 M | USA |
 |
C4 Therapeutics
CCCC
|
-2.31 | $ 3.0 | -4.76 % | $ 249 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
0.0726 | $ 1.67 | -0.6 % | $ 2.75 M | Israel |
 |
Cytokinetics, Incorporated
CYTK
|
-3.27 | $ 56.2 | 1.92 % | $ 6.75 M | USA |
 |
Curis
CRIS
|
-3.41 | $ 0.66 | -5.68 % | $ 8.69 M | USA |
 |
Exelixis
EXEL
|
13.2 | $ 71.0 | -1.04 % | $ 19.3 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-3.42 | - | -1.52 % | $ 24.7 M | USA |
 |
Amgen
AMGN
|
13.3 | $ 465.26 | 0.01 % | $ 250 B | USA |
 |
Biogen
BIIB
|
48.2 | $ 253.37 | -0.59 % | $ 37.1 B | USA |
 |
Edesa Biotech
EDSA
|
-0.0637 | $ 2.01 | -19.28 % | $ 11.4 M | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-15 | $ 15.12 | -0.72 % | $ 978 M | USA |